Greek
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
4 ipomeanol/καρκίνος
Ο σύνδεσμος αποθηκεύεται στο πρόχειρο
13 Αποτελέσματα
4-Ipomeanol: a novel investigational new drug for lung cancer.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
4-Ipomeanol (IPO) is the first agent to undergo preclinical development at the National Cancer Institute (NCI) based principally on a specific biochemical-biological rationale for clinical investigation as an antineoplastic agent targeted against lung cancer. This disease-specific development of IPO
Preclinical toxicology studies of 4-ipomeanol: a novel candidate for clinical evaluation in lung cancer.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
4-Ipomeanol (ipomeanol) is being developed as a potential antitumor agent to treat lung cancer. Ipomeanol produced a dose-related toxicity in CD2F1 mice, Fischer 344 rats, and beagle dogs. The LD50 in mice after a single iv dose of ipomeanol was 35 mg/kg in males and 26 mg/kg in females. Minimal
Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
The mammalian pulmonary toxin 4-ipomeanol (IPO) is activated by the cytochrome P450 system in bronchial Clara cells in animals. The resulting metabolites bind rapidly to macromolecules, producing localized cytotoxicity. IPO has in vitro and in vivo antitumor activity in non-small cell lung cancer
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
4-Ipomeanol (IPO), a naturally occurring pulmonary toxin, is the first cytotoxic agent to undergo clinical development based on a biochemical-biological rationale as an antineoplastic agent targeted specifically against lung cancer. This rationale is based on preclinical observations that metabolic
Optimization of process parameters for bioproduction, isolation and purification of 4-Ipomeanol from cell suspension cultures of Ipomoea batatas (L.) Lam.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
The secondary metabolite, 4-Ipomeanol from Sweet potato (Ipomoea batatas) is a potential chemotherapeutic agent for cancer. This study presents an efficient protocol for bioproduction of 4-ipomeanol, in large quantities without disturbing the natural biodiversity of I. batatas. Friable Calli from
Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
4-Ipomeanol (IPO) is a pulmonary-specific toxin that is metabolically activated by a cytochrome P450 pathway in lung tissue. In this study, IPO metabolism, as determined by measurement of [14C]IPO covalent binding, was evaluated in a diverse sampling of 18 established, human lung cancer cell lines
Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone pulmonary metabolism and tumorigenicity in mice by analogues of the investigational chemotherapeutic drug 4-ipomeanol.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
4-Ipomeanol (IPO) is an investigational chemotherapeutic drug with specific toxicity toward the lung. It is metabolically activated to reactive intermediates by cytochrome P450 enzymes present in Clara cells. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a highly carcinogenic
Synthesis and evaluation of a 18F-labeled 4-ipomeanol as an imaging agent for CYP4B1 gene prodrug activation therapy.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
We report the development of a (18)F-labeled 4-ipomeanol (4-IM), which is metabolized by the CYP4B1 enzyme, to image tumors and monitor enzyme-activating anticancer prodrugs. The fluorine-substituted derivative, 1-(3-furyl)-4-hydroxy-5-fluoro-1-pentanone (F-4-IM, 1), was synthesized from
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
OBJECTIVE
4-Ipomeanol (IPO; NSC 394438), a naturally occurring furan isolated from common sweet potatoes (Ipomoea batatas) infected with the fungus Fusarium solani was the first agent to be developed by the National Cancer Institute based on a biochemical-biological rationale as an anticancer agent
Cytochrome P450 4B1 (CYP4B1) as a target in cancer treatment.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
Cytochrome P450 4B1 (CYP4B1) plays crucial roles in biotransforming of xenobiotics. Its predominant extrahepatic expression has been associated with certain tissue-specific toxicities. However, the expressions of CYP4B1 in various cancers and hence their potential roles in cancer development were
DNA adducts of heterocyclic amines: formation, removal and inhibition by dietary components.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
The dietary mutagens 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) are carcinogenic in rodents. In F344 rats PhIP induces mammary tumors in females and colon tumors in males, while IQ induces tumors principally in the liver, Zymbal gland and
Natural pesticides and bioactive components in foods.
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
In this review, some common food plants and their toxic or otherwise bioactive components and mycotoxin contaminants have been considered. Crucifers contain naturally occurring components that are goitrogenic, resulting from the combined action of allyl isothiocyanate, goitrin, and thiocyanate.
Ipomeanol analogs as chemopreventive agents: effect on the in vitro metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a tobacco-specific, powerful, organospecific lung carcinogen. 4-Ipomeanol (IPO) is an investigational chemotherapeutic drug with specific toxicity towards the lung. We hypothesized that non-toxic analogs of IPO could be competitive inhibitors
Η πληρέστερη βάση δεδομένων φαρμακευτικών βοτάνων που υποστηρίζεται από την επιστήμη
- Λειτουργεί σε 55 γλώσσες
- Βοτανικές θεραπείες που υποστηρίζονται από την επιστήμη
- Αναγνώριση βοτάνων με εικόνα
- Διαδραστικός χάρτης GPS - ετικέτα βότανα στην τοποθεσία (σύντομα)
- Διαβάστε επιστημονικές δημοσιεύσεις που σχετίζονται με την αναζήτησή σας
- Αναζήτηση φαρμακευτικών βοτάνων με τα αποτελέσματά τους
- Οργανώστε τα ενδιαφέροντά σας και μείνετε ενημερωμένοι με την έρευνα ειδήσεων, τις κλινικές δοκιμές και τα διπλώματα ευρεσιτεχνίας
Πληκτρολογήστε ένα σύμπτωμα ή μια ασθένεια και διαβάστε για βότανα που μπορεί να βοηθήσουν, πληκτρολογήστε ένα βότανο και δείτε ασθένειες και συμπτώματα κατά των οποίων χρησιμοποιείται.
* Όλες οι πληροφορίες βασίζονται σε δημοσιευμένη επιστημονική έρευνα
